REGENXBIO Inc. RGNX
8.47 USD +0.78 (+10.14%)
At closeNov 11, 2026, 5:53 PM EST
8.40 -0.07 -0.83%
After hours · Nov 11, 5:53 PM ET
7.62 Day range 8.88
5.46 52-week range 16.19
- YTD
- -41.18%
- 1 year
- -26.67%
News
seekingalpha.com Regenxbio: 2 Major Catalysts Could Change The Investment Case Regenxbio Inc. is Buy-rated, with upcoming ATMOSPHERE and ASCENT readouts and RGX-202 regulatory milestones as key near-term catalysts. RGNX faces a structural revenue headwind from ZOLGENSMA royalty…
marketbeat.com REGENXBIO Q3 Earnings Call Highlights REGENXBIO NASDAQ: RGNX is approaching pivotal trial results for its eye disease gene therapy and preparing a U.S. application for its Duchenne muscular dystrophy treatment, executives said during the…
seekingalpha.com REGENXBIO Inc. (RGNX) Q3 2026 Earnings Call Transcript REGENXBIO Inc. (RGNX) Q3 2026 Earnings Call Transcript
zacks.com Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue Estimates Regenxbio (RGNX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $1.35. This compares to a loss of $1.2 per share a year ago.
benzinga.com Regenxbio Q3 2026 Earnings Call Transcript Regenxbio (NASDAQ:RGNX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…
benzinga.com Regenxbio Q3 EPS $(0.62) Beats $(1.26) Estimate, Sales $9.162M Miss $10.868M Estimate Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(1.26) by 50.79 percent. This is a 48.33 percent increase over losses of $(1.20)…
prnewswire.com REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q1 2027, with potential accelerated approval in 2H 2027 Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE ® and…
zacks.com Wall Street Analysts See a 214.55% Upside in Regenxbio (RGNX): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 214.6% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the…
zacks.com 4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates Four biotech stocks, including TG Therapeutics and Immunome, show positive Earnings ESPs and favorable Zacks Ranks, positioning them for potential third-quarter earnings beats.
benzinga.com Full Transcript: Regenxbio Q2 2026 Earnings Call Regenxbio (NASDAQ:RGNX) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For…
benzinga.com Mizuho Initiates Coverage On Regenxbio with Outperform Rating, Announces Price Target of $22 Mizuho analyst Graig Suvannavejh initiates coverage on Regenxbio (NASDAQ:RGNX) with a Outperform rating and announces Price Target of $22.- benzinga.com Reported Earlier, REGENXBIO Presents Three-Year Sura-Vec Data Showing Majority Of NPDR Participants Achieved Greater Than 2-Step DRSS Improvement, No Vision-Threatening Events Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no…
benzinga.com REGENXBIO Says All Ongoing Patent Litigation Regarding Patents-In-Suit To Be Terminated With Prejudice; Agrees Not To Sue Sarepta Or Affiliates Over Existing Elevidys Or AAVrh74-Based Capsids On September 23, 2026, REGENXBIO Inc. (the "Company") and The Trustees of the University of Pennsylvania ("UPenn") entered into a Settlement Agreement (the "Settlement Agreement") with Sarepta
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-market session. The company's market cap stands at $10.3 million. Aethlon Medical (NASDAQ:AEMD) stock moved…
benzinga.com HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $21 HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $23 to $21.- benzinga.com Baird Maintains Outperform on Regenxbio, Lowers Price Target to $29 Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and lowers the price target from $32 to $29.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Innovative Eyewear (NASDAQ:LUCY) stock rose 63.6% to $1.12 during Monday's regular session. The market value of their outstanding shares is at $5.8 million. Picard Medical (AMEX:PMI) shares…
benzinga.com Crude Oil Down 3%; XPeng Shares Fall After Q2 Results US stocks traded mixed with the Dow Jones index gaining over 150 points. Consumer staples shares jumped while information technology stocks fell. XPeng Inc shares fell 7% due to wider than expected…
benzinga.com Regenxbio Hits Regulatory Roadblock After FDA Puts RGX-121 on Hold Regenxbio stock drops over 23% following an FDA clinical hold on its Hunter Syndrome gene therapy RGX-121 due to spine MRI findings.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Picard Medical (AMEX:PMI) shares moved upwards by 34.6% to $4.32 during Monday's pre-market session. The company's market cap stands at $6.5 million. As per the press release, Q2 earnings…
benzinga.com The FDA Places Clinical Hold On Regenxbio's RGX-121 Following Asymptomatic Spine MRI Findings In Five Participants In CAMPSIITE Study In Mucopolysaccharidosis Type II Patients REGENXBIO Inc. (NASDAQ:RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucopolysaccharidosis type II (MPS II), also known…
benzinga.com This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday Wall Street analysts upgraded PTGX, LECO, and JHX. See analyst ratings and price targets for these stocks.
benzinga.com HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $23 HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $26 to $23.
benzinga.com This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday Wall Street analysts changed outlook on top names. For rating changes, check our analyst ratings page. See analysts' views on ADIG, TSEM and more
benzinga.com This HubSpot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Top Wall Street analysts changed outlook on top names. For all changes & stock ratings, see analyst ratings page. Some stocks downgraded & price targets lowered.
benzinga.com Barclays Downgrades Regenxbio to Equal-Weight, Maintains Price Target to $12 Barclays analyst Eliana Merle downgrades Regenxbio (NASDAQ:RGNX) from Overweight to Equal-Weight and maintains the price target from $12 to $12.
benzinga.com Regenxbio Q2 EPS $0.43 Beats $(0.03) Estimate, Sales $108.019M Miss $117.127M Estimate Regenxbio (NASDAQ:RGNX) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $(0.03) by 1533.33 percent. This is a 131.16 percent increase over losses of…
benzinga.com These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refinancing deals and short squeezes.
benzinga.com Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments REGENXBIO announced positive long-term sura-vec trial data for wet AMD and diabetic retinopathy, alongside a $100 million offering.
benzinga.com Crude Oil Surges 4%; Travelers Posts Upbeat Q2 results Nasdaq falls over 200 points, Dow down 0.28%, S&P 500 drops 0.51%. Energy shares up 1.4%, communication services stocks down 3.1%. Travelers Companies beats Q2 estimates. Southland Holdings up 51%,…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market session. The market value of their outstanding shares is at $112.9 million. Barinthus Biotherapeutics…
benzinga.com Intuitive Surgical, Netflix And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures lower, Nasdaq 100 down 2%. Intuitive Surgical shares dip 11.3% after Q2 earnings beat estimates. Other stocks also falling in pre-market.- benzinga.com Market-Moving News for July 17th NFLX: 10% | Netflix shares are trading lower after the company reported worse-than-expected Q2 sales results and issued Q3 guidance below estimates. Also, the company narrowed its FY26 sales guidance…
- benzinga.com REGENXBIO Prices Offering Of 10,003,889 Shares At $9.00 Per Share And 1,111,111 Pre-Funded Warrants At $8.9999 Per Warrant The gross proceeds to REGENXBIO from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by REGENXBIO, are expected to be approximately…
benzinga.com Why Callan JMB Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket Callan JMB Inc (CJMB) shares jumped 63.8% in pre-market trading after announcing a strategic partnership with Alabama State University.- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-market session. The company's market cap stands at $3.3 million. Stereotaxis (AMEX:STXS) stock increased…
benzinga.com REGENXBIO Plans To Commence $100M Common Stock Offering REGENXBIO Inc. (NASDAQ:RGNX) today announced that it intends to offer and sell, subject to market conditions, $100 million of its common stock in an underwritten public offering. The offering is…- benzinga.com REGENXBIO Announces First Patient Dosed In Phase IIb/III NAAVIGATE Clinical Trial Of Investigational Surabgene Lomparvovec In Diabetic Retinopathy Using Suprachoroidal Delivery; REGENXBIO To Receive $100M From Abbvie For This Milestone New long-term data from diabetic retinopathy and wet AMD programs to be presented at American Society of Retina Specialists (ASRS) 2026ROCKVILLE, Md., June 29, 2026 /PRNewswire/ -- REGENXBIO Inc.…
benzinga.com What's Going On With Capricor Therapeutics Stock On Friday? Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its Duchenne muscular dystrophy therapy.- benzinga.com HC Wainwright & Co. Reiterates Buy on Regenxbio, Maintains $26 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Regenxbio (NASDAQ:RGNX) with a Buy and maintains $26 price target.
- benzinga.com REGENXBIO Completes Dosing In Its Confirmatory Study Of RGX-202 Gene Therapy For Duchenne Muscular Dystrophy Confirmatory study completed ahead of schedule due to strong patient demand and robust investigator interestOn track to initiate BLA in Q3 2026 under the accelerated approval pathway supporting…
benzinga.com Baird Maintains Outperform on Regenxbio, Raises Price Target to $32 Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and raises the price target from $27 to $32.- benzinga.com Leerink Partners Maintains Outperform on Regenxbio, Raises Price Target to $18 Leerink Partners analyst Mani Foroohar maintains Regenxbio (NASDAQ:RGNX) with a Outperform and raises the price target from $17 to $18.
benzinga.com Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy FDA reverses its rejection of Regenxbio Navsunli, allowing the company to refile its gene therapy application.- benzinga.com REGENXBIO Says FDA Path Opens for Hunter Syndrome Gene Therapy, Plans Quick FDA Resubmission for One-Time Rare Disease Treatment REGENXBIO Inc. (NASDAQ:RGNX) today announced it has aligned with the U.S. Food and Drug Administration (FDA) regarding the next steps needed for a potential accelerated approval of NAVSUNLI™…
- benzinga.com Market-Moving News for June 22nd SAGT: 124% | Sagtec Global CEO's 1.5M Share Acquisition And $1.56M Private Placement Coincide With FY2026 Guidance Of 35% Revenue Growth To $25.78M RGNX: 32% | 'FDA Will Reverse Rejection of Third…
- benzinga.com HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $26 HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $30 to $26.
- benzinga.com B of A Securities Maintains Buy on Regenxbio, Lowers Price Target to $14 B of A Securities analyst Geoff Meacham maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $25 to $14.
- benzinga.com Barclays Maintains Overweight on Regenxbio, Lowers Price Target to $12 Barclays analyst Gena Wang maintains Regenxbio (NASDAQ:RGNX) with a Overweight and lowers the price target from $37 to $12.
benzinga.com Nasdaq Jumps Over 200 Points; Dillard's Shares Gain After Q1 Earnings